Data / Drug companies / Isoproterenol hydrochloride
Isoproterenol hydrochloride: 13 companies and 24 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Isoproterenol hydrochloride is listed in the FDA National Drug Code Directory by 13 companies, with 24 products in commercial distribution. 24 of the products (100.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, solution; injection, and the newest product started marketing on January 15, 2025.
The request: Get every company that lists isoproterenol hydrochloride in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 13
- Products
- 24
- Generic (ANDA) products
- 24 (100.0%)
- Application numbers
- 10
- Routes
- Intravenous, Intramuscular, Intracardiac, Subcutaneous
- Brand names
- Isoproterenol
- openFDA record search
- api.fda.gov
Companies that list isoproterenol hydrochloride
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Nordic Pharma, Inc. | 4 | injection, solution | Generic drugs (ANDA) | June 1, 2024 |
| Amneal Pharmaceuticals LLC | 2 | injection, solution | Generic drugs (ANDA) | October 22, 2018 |
| Amphastar Pharmaceuticals, Inc. | 2 | injection, solution | Generic drugs (ANDA) | June 18, 2018 |
| Cipla USA Inc. | 2 | injection, solution | Generic drugs (ANDA) | June 26, 2018 |
| Eugia US LLC | 2 | injection, solution | Generic drugs (ANDA) | February 9, 2021 |
| Gland Pharma Limited | 2 | injection, solution | Generic drugs (ANDA) | October 3, 2024 |
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 2 | injection, solution | Generic drugs (ANDA) | November 19, 2021 |
| Micro Labs Limited | 2 | injection | Generic drugs (ANDA) | May 1, 2021 |
| Nexus Pharmaceuticals LLC | 2 | injection, solution | Generic drugs (ANDA) | August 3, 2017 |
| Armas Pharmaceuticals Inc. | 1 | injection | Generic drugs (ANDA) | August 6, 2021 |
| Avenacy, LLC | 1 | injection, solution | Generic drugs (ANDA) | May 15, 2024 |
| KVK-Tech, Inc. | 1 | injection, solution | Generic drugs (ANDA) | September 25, 2023 |
| Sagent Pharmaceuticals | 1 | injection, solution | Generic drugs (ANDA) | January 15, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 21 | 87.5% |
| Injection | 3 | 12.5% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 24 | 100% |
Pharmacologic classes
| Class | Products |
|---|---|
| beta-Adrenergic Agonist | 24 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.